Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ clinical effectiveness research

This article was originally published in The Gray Sheet

Executive Summary

Consolidated appropriations bill signed into law Dec. 8 provides $15 mil. to Agency for Healthcare Research & Quality for FY 2005 clinical effectiveness research - significantly less than the $50 mil. authorized by the Medicare Modernization Act for the previous fiscal year. The FY 2004 amount was never funded. AdvaMed and Guidant are among stakeholders that submitted comments on AHRQ's research agenda, which initially will focus on pharmaceuticals (1"The Gray Sheet" July 5, 2004, p. 13). Separately, on Dec. 9, AHRQ issued a Federal Register notice inviting nominations of topics for evidence reports and technology assessments. Nominations are due Jan. 31...

You may also be interested in...



AdvaMed Urges “Broad-Based Approach” To AHRQ Research

AHRQ's comparative clinical effectiveness research, authorized by the Medicare Modernization Act, should invoke a broader range of data than most randomized controlled trials currently offer, AdvaMed contends

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

UsernamePublicRestriction

Register

MT021290

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel